immune checkpoint inhibition

Atezolizumab - Avelumab - Durvalumab - Durvalumab + tremelimumab - Ipilimumab - Nivolumab - Pembrolizumab      

Select            
Trial Studied trt Control trt patientstagsROB Trial result

gastric or gastro-oesophageal junction cancer (advanced)

nivolumab
ATTRACTION-2, 2017      NCTnivolumabplaceboLow risk of bias suggesting
pembrolizumab
KEYNOTE-059 single-arm      NCTpembrolizumabnil -
Keynote 061, 2018    NCTpembrolizumabpaclitaxel2L 2nd line PD-L1 positive Risk of bias negative

Head and neck cancer

nivolumab
Checkmate-141, 2016      NCTnivolumabstandard treatment2L 2nd line platinum failure Risk of bias conclusive
pembrolizumab
KEYNOTE-040    NCTpembrolizumabstandard treatment2L 2nd line Risk of bias negative

lung cancer (metastatic)

atezolizumab
IMpower150 (WT), 2018      NCTatezolizumab + bevacizumabbevacizumab (on top platinum-based CT)1L 1st line nonsquamous NSCLC Risk of bias suggesting
IMpower150 (Teff), 2018        NCTatezolizumab + bevacizumabbevacizumab (on top platinum-based CT)1L, Teff 1st line nonsquamous NSCLC Risk of bias suggesting
POPLAR Phase 2 atezolizumab, 2016    NCTatezolizumabdocetaxel2L 2nd+ line platinum failure Risk of bias negative
OAK, 2016      NCTatezolizumabdocetaxel2L 2nd+ line platinum failure Risk of bias suggesting
durvalumab
PACIFIC, 2017      NCTdurvalumabplacebomaintenance maintenance therapy Low risk of bias conclusive
ARCTIC PD-L1 negative, 2018    NCTdurvalumab + tremelimumabStandard of Care3L, PD-L1 negative -
ipilimumab
Reck, 2016      NCTipilimumab + chemotherapyplacebo + chemotherapySCLCLow risk of bias -
Govindan, 2017      NCTipilimumab + chemotherapyplacebo + chemotherapy1LLow risk of bias negative
phase 2 (phased ipilimumab), 2012     ipilimumab + chemotherapyplacebo + chemotherapyLow risk of bias -
nivolumab
CheckMate 057, 2015      NCTnivolumabdocetaxel2L, non squamous 2nd+ line nonsquamous NSCLC Risk of bias suggesting
CheckMate 017, 2015    NCTnivolumabdocetaxel2L, squamous 2nd+ line squamous NSCLC Risk of bias suggesting
CheckMate 026, 2016    NCTnivolumabplatinum-based CT1L, PDL1 positive 1st line PD-L1 positive Risk of bias negative
CheckMate 227 (nivolumab + CT), 2018    NCTnivolumab + CTplatinum-based CT1L, PDL1 negatif 1st line PD-L1 negatif suggesting
CheckMate 227 (High Tumor Mutational Burden), 2018      NCTnivolumab + ipilimumabplatinum-based CT1L, hi TMB 1st line Risk of bias suggesting
pembrolizumab
Keynote 010 10mg, 2015      NCTpembrolizumab 10mgdocetaxel2L, PD-L1 positive 2nd+ line Risk of bias suggesting
Keynote 010 2mg, 2015      NCTpembrolizumab 2mgdocetaxel2L, PD-L1 positive 2nd+ line Risk of bias suggesting
Keynote 042 (>=1%), 2018    NCTpembrolizumabplatinum-based CT1L, PDL1 positive 1st line PD-L1 positive Risk of bias suggesting
Keynote 024, 2015      NCTpembrolizumabplatinum-based CT1L, PDL1 positive 1st line PD-L1 positive Risk of bias suggesting
Keynote 042 (>=50%), 2018    NCTpembrolizumabplatinum-based CT1L, PDL1 positive 1st line PD-L1 positive Risk of bias suggesting
Keynote 042 (>=20%), 2018    NCTpembrolizumabplatinum-based CT1L, PDL1 positive 1st line PD-L1 positive Risk of bias suggesting
KEYNOTE-021 phase 2, 2016      NCTpembrolizumab + platinum-based CTplatinum-based CT1L nonsquamous 1st line nonsquamous NSCLC Exploratory suggesting
Keynote 189, 2018      NCTpembrolizumab + platinum-based CTplatinum-based CT1L PD-L1 positive nonsquamous 1st line nonsquamous NSCLC Low risk of bias conclusive
Keynote 407, 2018    NCTpembrolizumanb + CTplatinum-based CT1L squamous squamous NSCLC Risk of bias suggesting

melanoma

ipilimumab
Robert, 2011      NCTipilimumab + dacarbazinedacarbazine1L 1st line Low risk of bias conclusive
Hodi (ipi + gp100), 2010      NCTipi + gp100gp1002L 2nd line Risk of bias suggesting
Hodi (ipi alone), 2010      NCTipilimumab 3 mg/kggp1002L 2nd line Risk of bias suggesting
EORTC 18071 (Eggermont), 2015        NCTipilimumabplaceboadjuvant adjuvant Low risk of bias conclusive
nivolumab
CheckMate 037 (Weber), 2015      NCTnivolumabchemotherapy2L, anti-CTLA-4 failure 2nd line Risk of bias suggesting
CheckMate 066 (Robert), 2015      NCTnivolumabdacarbazine1L 1st line Low risk of bias conclusive
CheckMate 238, 2017      NCTnivolumabipilimumabadjuvant adjuvant Low risk of bias conclusive
CheckMate 067 (nivo vs ipi), 2015      NCTnivolumabipilimumab1L 1st line Low risk of bias conclusive
CheckMate 067 (nivo + ipi vs ipi), 2015    NCTnivolumab + ipilimumabipilimumab1L 1st line Low risk of bias conclusive
Postow, 2015      NCTnivolumab + ipilimumabipilimumab1L 1st line Exploratory -
CheckMate 067 (nivo + ipi vs nivo), 2015      NCTnivolumab + ipilimumabnivolumab1L 1st line Exploratory -
pembrolizumab
KEYNOTE 002 (10mg/kg Q3W), 2015      NCTpembrolizumab 10mg/kgchemotherapy2L 2nd line Exploratory suggesting
KEYNOTE 002 (2mg/kg Q3W), 2015      NCTpembrolizumab 2mg/kgchemotherapy2L 2nd line Exploratory suggesting
KEYNOTE-006 (every 2W), 2015      NCTpembrolizumab (every 2W)ipilimumab1L 1st line Risk of bias suggesting
KEYNOTE-006 (every 3W), 2015      NCTpembrolizumab (every 3W)ipilimumab1L 1st line Risk of bias suggesting
KEYNOTE-001, 2014      NCTpembrolizumab 2mg/kgpembrolizumab 10mg/kg2L 2nd line Exploratory negative
KEYNOTE-054, 2018      NCTpembrolizumabplaceboadjuvant adjuvant Low risk of bias conclusive

multiple myeloma

pembrolizumab
KEYNOTE-185, 2018    NCTpembrolizumab, lenalidomide, dexametahsonelenalidomide, dexamethasonenot eligible for ASCTRisk of bias remark
KEYNOTE-183, 2018    NCTpembrolizumab + pomadoline + dexamethasonepomadoline + dexamethasonerrMMRisk of bias negative

renal-cell carcinoma (advanced)

nivolumab
Chekmate 025 (Motzer), 2015      NCTnivolumabeverolimus2LRisk of bias suggesting
CheckMate-214, 2017      NCTnivolumab + ipilimumabsunitinib1LRisk of bias conclusive

urothelial carcinoma (advanced)

atezolizumab
IMvigor211 (IC2/3)      NCTatezolizumabchemotherapy2nd line, IC2/3 2nd line Risk of bias suggesting
IMVIGOR-130 (monotherapy)    NCTatezolizumabcontrolfirst line 1st line Risk of bias remark
IMvigor210 single-arm      NCTatezolizumabnil1st and 2nd line 1st line 2nd line Exploratory -
durvalumab
durvalumab phase 1/2 single-arm   durvalumabnil2nd line 2nd line Exploratory -
nivolumab
Checkmate 275 single-arm      NCTnivolumabnil2nd line 2nd line Exploratory -
pembrolizumab
KEYNOTE-052, 2017 single-arm      NCTpembrolizumab 1st line Risk of bias -
KEYNOTE-045, 2017    NCTpembrolizumabchemotherapy2nd line 2nd line Risk of bias suggesting
Keynote 361 monotherapy    NCTpembrolizumabchemotherapyfirst lineremark